Novel drugs and intervention strategies for the treatment of chronic kidney disease. - sprookjes - yvandenbroek - TriplyDB

Novel drugs and intervention strategies for the treatment of chronic kidney disease.

Novel drugs and intervention strategies for the treatment of chronic kidney disease.

http://www.wikidata.org/entity/Q37219043

about

Personalized Medicine: New Perspectives for the Diagnosis and the Treatment of Renal Diseases Waist to height ratio is an independent predictor for the incidence of chronic kidney disease High glucose repatterns human podocyte energy metabolism during differentiation and diabetic nephropathy.Inflammasome Activation in Chronic Glomerular Diseases.Beneficial effects of Fu-Zheng-Qu-Zhuo oral liquid combined with standard integrated therapy in patients with chronic kidney disease (stage 3-4): A randomized placebo-controlled clinical trial.

P2860

Q33838866-E8B29296-B4EC-4E9A-83EC-C9E9530CED8B Q35095602-1064B7F4-A6E1-4746-B880-BC15D72C871F Q37510406-BA6845F1-9E39-4E05-800E-91F01F45FC7F Q38931056-4A3C5E31-873A-4793-A4DD-85754A10CEDA Q40125871-2A1D93FD-316B-4EFD-971C-30C611A13F34

P2860

Novel drugs and intervention strategies for the treatment of chronic kidney disease.

http://www.wikidata.org/entity/Q37219043

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on October 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Novel drugs and intervention strategies for the treatment of chronic kidney disease.

@en

Novel drugs and intervention strategies for the treatment of chronic kidney disease.

@nl

type

label

Novel drugs and intervention strategies for the treatment of chronic kidney disease.

@en

Novel drugs and intervention strategies for the treatment of chronic kidney disease.

@nl

prefLabel

Novel drugs and intervention strategies for the treatment of chronic kidney disease.

@en

Novel drugs and intervention strategies for the treatment of chronic kidney disease.

@nl

P1433

Q37219043-A65411A0-CD61-4449-9075-5151D281EC8E

P1476

Q37219043-161208CD-D411-4364-9D14-86822B752E58

P2093

Q37219043-144EA204-7F42-49B7-87A6-F68493A87419

Q37219043-DF9F35E8-9E5D-4E80-8C46-9176B319F618

P2860

Q37219043-0356553A-1512-4974-B0D7-6C3C1F688738

Q37219043-0899C5B0-E107-4A58-A5E5-95C0F969A61A

Q37219043-0DB23456-CA88-471C-AD45-A8810B66CBB0

Q37219043-0E4E3522-208B-4E58-972D-7B386347486D

Q37219043-0FD87512-958B-4D10-9F71-3A6DE9880147

Q37219043-112DA6A2-216C-47FC-89E9-86EEF5CD2817

Q37219043-122D02BB-4EBD-40A8-A838-084A057AAEF5

Q37219043-161E35B4-48D6-43F2-A2A1-ABDEFB44EDCC

Q37219043-1A0D7114-0819-4A0A-B0B9-01167530B96C

Q37219043-1CA0E4A6-4B09-4531-8F63-CB1CACD2E708

P304

Q37219043-511E5173-2104-4E9B-BAC3-F23106B60319

P31

Q37219043-B49C0025-1F41-46AA-8851-BD483AD7E889

P356

Q37219043-E9DC377B-5AB4-4F7E-BD48-86C34BBE6F1B

P407

Q37219043-E6B455E5-BD61-4184-823F-C53EC5E94C75

P433

Q37219043-BED68F89-87E8-494B-835C-3C9C30654692

P478

Q37219043-158C1ADF-3A12-448C-A841-FFFE733F9AFF

P577

Q37219043-06B50984-4F8F-41B8-B3F6-6F29D615F0F0

P698

Q37219043-F252DFBA-41BD-4224-995F-0AC8A5A730CD

P932

Q37219043-7E9A0715-07E2-468D-B416-A0D6062529A1

P356

P1433

British Journal of Clinical Pharmacology

P1476

Novel drugs and intervention strategies for the treatment of chronic kidney disease.

@en

P2093

Dick de Zeeuw

http://www.w3.org/2001/XMLSchema#string

Hiddo Jan Lambers Heerspink

http://www.w3.org/2001/XMLSchema#string

P2860

A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule.

Effect of allopurinol in chronic kidney disease progression and cardiovascular risk

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

Cardiorenal end points in a trial of aliskiren for type 2 diabetes

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

Telmisartan, ramipril, or both in patients at high risk for vascular events.

The HALT polycystic kidney disease trials: design and implementation.

Avosentan for overt diabetic nephropathy.

Dietary protein restriction and the progression of chronic renal disease: what have all of the results of the MDRD study shown? Modification of Diet in Renal Disease Study group.

P304

536-550

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/BCP.12195

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

76

http://www.w3.org/2001/XMLSchema#string

P577

2013-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23802504

http://www.w3.org/2001/XMLSchema#string

P932

3791977

http://www.w3.org/2001/XMLSchema#string